Obesity and atrial fibrillation: new treatment options

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The prevalence of obesity and atrial fibrillation (AF), which are inextricably linked, is rapidly growing worldwide. A number of clinical studies have shown that weight loss significantly reduces the risk of arrhythmia and its natural progression. Along with weight loss, the tactics of managing patients with obesity and AF include risk factor correction, anticoagulant therapy for increased risk of thromboembolic complications, and control of arrhythmia symptoms. One of the significant difficulties in treating patients with obesity and AF is the administration of a large dose of an antiarrhythmic drug to stop and prevent paroxysms of arrhythmia. In obese patients, there is a change in the volume of distribution and excretion of drugs, which in turn affects the half-life of the drug. Correction of cardiovascular risk factors in obese patients with AF includes therapy aimed at reducing the activity of the renin-angiotensin-aldosterone system, and treating carbohydrate and lipid metabolism disorders.

Full Text

Restricted Access

About the authors

Aida I. Tarzimanova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: tarzimanova@mail.ru
ORCID iD: 0000-0001-9536-8307

Dr. Sci. (Med.), Professor, Department of Faculty Therapy No. 2, N.V. Sklifosovsky Institute of Clinical Medicine

Russian Federation, Moscow

Valeria F. Valitova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: tarzimanova@mail.ru
ORCID iD: 0009-0009-0729-7760

Resident, Department of Faculty Therapy No. 2, N.V. Sklifosovsky Institute of Clinical Medicine

Russian Federation, Moscow

Ksenia O. Speranskaya

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: tarzimanova@mail.ru
ORCID iD: 0009-0001-9793-4963

Student, N.V. Sklifosovsky Institute of Clinical Medicine

Russian Federation, Moscow

Esmira Sh. Samedova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: tarzimanova@mail.ru
ORCID iD: 0009-0008-8458-3739

Student, N.V. Sklifosovsky Institute of Clinical Medicine

Russian Federation, Moscow

Asiyat A. Okhtova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: tarzimanova@mail.ru
ORCID iD: 0009-0006-1818-9480

Student, N.V. Sklifosovsky Institute of Clinical Medicine

Russian Federation, Moscow

References

  1. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний (национальные клинические рекомендации). Под ред. Шляхто Е.В., Недогода С.В., Конра-ди А.О. Санкт-Петербург, 2017. [Diagnostics, treatment, prevention of obesity and associated diseases (national clinical guidelines). Edited by Shlyakhto E.V., Nedogoda S.V., Konradi A.O. St. Petersburg, 2017. (In Russ.)].
  2. Shu H., Cheng J., Li N., et al Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance. Cardiovasc Diabetol. 2023 Jul 29;22(1):192. doi: 10.1186/s12933-023-01913-5.
  3. Wang T.J., Parise H., Levy D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471–7. doi: 10.1001/jama.292.20.2471.
  4. Frost L., Hune L.J., Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the danish Diet, Cancer, and Health Study. Am J Med. 2005;118:489–95. doi: 10.1016/j.amjmed.2005.01.031.
  5. Karasoy D., Bo Jensen T., Hansen M.L., et al. Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. Europace. 2013;15:781–6. doi: 10.1093/europace/eus422.
  6. Heijman J., Voigt N., Nattel S., Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114:1483–99. doi: 10.1161/CIRCRESAHA.114.30222.
  7. Ueda N., Yamamoto M., Honjo H., et al. The role of gap junctions in stretch-induced atrial fibrillation. Cardiovasc Res. 2014;104:364–70. doi: 10.1093/cvr/cvu202.
  8. Qiu D., Peng L., Ghista D.N., Wong K.K.L. Left Atrial Remodeling Mechanisms Associated with Atrial Fibrillation. Cardiovasc Eng Technol. 2021;12:361–72. doi: 10.1007/s13239-021-00527-w.
  9. Tsioufis C., Konstantinidis D., Nikolakopoulos I., et al. Biomarkers of Atrial Fibrillation in Hypertension. Curr Med Chem. 2019;26:888–97. doi: 10.2174/092986732466617100615551.
  10. Samman Tahhan A., Sandesara P.B., Hayek S.S., et al. Association between oxidative stress and atrial fibrillation. Heart Rhythm. 2017;14:1849–55. doi: 10.1016/j.hrthm.2017.07.028.
  11. Khawaja O., Bartz T., Ix J.H., et al. Plasma free fatty acids and risk of atrial fibrillation (from the Cardio- vascular Health Study). Am J Cardiol. 2012;110(2):212–6. doi: 10.1016/j.amjcard.2012.03.010.
  12. Middeldorp M.E., Pathak R.K., Meredith M., et al. PREVEntion and regReSsive effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018;20:1929–35. doi: 10.1093/europace/euy117.
  13. Jamaly S., Carlsson L., Peltonen M., et al. Bariatric surgery and the risk of New-Onset Atrial Fibrillation in Swedish obese subjects. J Am Coll Cardiol. 2016;68:2497–504. doi: 10.1016/j.jacc.2016.09.940.
  14. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. Atrial fibrillation and flutter. Clinical guidelines 2020. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.)].doi: 10.15829/1560-4071-2021-4594.
  15. Фомина И.Г., Тарзиманова А.И., Ветлужский А.В., Абрамова А.А. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. ПРОМЕТЕЙ – открытое, мультицентровое, пилотное исследование в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2005;4:65–69. [Fomina I.G., Tarzimanova A.I., Vetluzhsky A.V., Abramova A.A. Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II). Cardiovascular Therapy and Prevention. 2005;4(5):62–65. (In Russ.)].
  16. Миллер О.Н., Старичков С.А., Поздняков Ю.М. и др. Эффективность и безопасность применения пропафенона (Пропанорма®) и амиодарона (Кордарона®) у больных с фибрилляцией предсердий на фоне артериальной гипертонии, ишемической болезни сердца и хронической сердечной недостаточности с сохраненной систолической функцией левого желудочка. Российский кардиологический журнал. 2010;4(84):56–72. Miller O.N., Starichkov S.A., Pozdnyakov Yu.M., et al. Effectiveness and safety of propafenone (Propanorm®) and amiodarone (Cordarone®) in patients with atrial fibrillation, arterial hypertension, coronary heart disease, and chronic heart failure with intact left ventricular systolic function. Russian Journal of Cardiology. 2010;(4):55–71. (In Russ.)].
  17. Karajamaki A.J., Patsi O.P., Savolainen M., et al. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS One. 2015;10(11):e0142937.
  18. Маевская М.В., Котовская Ю.В., Ивашкин В.Т. и др. Национальный консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;2:216–253. [Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T., et al. National consensus for physicians on the management of adult patients with non-alcoholic fatty liver disease and its main comorbid conditions. Terapevticheskiy arkhiv. 2022;2:216–253. (In Russ.)].
  19. Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю. с соавт. Исследование РАКУРС: повышение эффективности и безопасности терапии статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей с помощью урсодеоксихолевой кислоты. Терапевтический архив. 2014;12:48–52. [Martsevich S.Yu., Kutishenko N.P., Drozdova L.Yu. et al. The RAKURS study: improving the efficacy and safety of statin therapy in patients with liver, gallbladder, and/or biliary tract diseases using ursodeoxycholic acid. Terapevticheskiy arkhiv. 2014;12:48–52. (In Russ.)].
  20. Nadinskaia M., Maevskaya M., Ivashkin V., et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959–75. doi: 10.3748/wjg.v27.i10.959.
  21. von Haehling S., Schefold J.C., Jankowska E.A., et al. Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol. 2012;59:585–592.
  22. Rainer P.P., Primessnig U., Harenkamp S., et al. Bile acids induce arrhythmias in human atrial myocardium-implications for altered serum bile acid composition in patients with atrial fibrillation. Heart. 2013;99:1685–1692.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media